Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared an article on X about a paper by A. Garrido-Castro et al. published in Annals of Oncology:
Title: SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
Authors: A. Garrido-Castro, S. Kim, T. Li, J. Desrosiers, R. Nanda, Y. Abdou, A. Clark, R. Sacks, T. O’Connor, N. Sinclair, S. Lo, G. Augdahl, E. Wrabel, M. DiLullo, T. Rahman, A. Patel, M. Hughes, J. Baginska, P. Lange, T. O’Meara, T. Keenan, A. Gorthi, A. D’Ippolito, C. Painter, M. Eaton, J. Barrett, B. Koca, P. Kurnia, A. Perry, J. Gomez Tejeda Zanudo, M. He, D. Dillon, N. Lin, H. Burstein, E. Mittendorf, R. Jeselsohn, D. Rimm, N. Tayob, S. Tolaney
Read the Full Article.
You can also read:
HER2-Low Subclones Drive T-DXd Resistance in HER2-Heterogeneous Breast Cancer Models
